Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies reported Q3 2026 revenue of $83.9 million, down 10.7% year-over-year but beating consensus estimates by 16.81%. The company posted EPS of $0.02 versus expectations of -$0.10, representing a 120% surprise. MRD revenue grew 27.8% to $72.57 million, while Immune Medicine revenue declined 69.5% to $11.34 million. The stock holds a Zacks Rank #3 (Hold) rating.